Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeff Settleman

Showing results (1-10 of 65) with videos related to

Pageof 7
Sort By:
Oncotarget|February 7, 2015
Predicting response to HER2 kinase inhibitionJeff Settleman
Seminars in Oncology|April 28, 2009
Cell culture modeling of genotype-directed sensitivity to selective kinase inhibitors: targeting the anaplastic lymphoma kinase (ALK)Jeff Settleman
Cancer Cell|October 6, 2009
A therapeutic opportunity in melanoma: ErbB4 makes a mark on skinJeff Settleman
Genome Medicine|July 18, 2014
Optimizing the treatment of BRAF mutant melanomaJeff Settleman
Nature|January 7, 2016
Cancer: Bet on drug resistanceJeff Settleman
BMC Medicine|December 17, 2009
Integrating complex genomic datasets and tumour cell sensitivity profiles to address a 'simple' question: which patients should get this drug?Cyril Benes, Jeff Settleman
Current Biology : CB|September 28, 2010
Cancer: miRNA addiction - depending on life's little thingsDavid Dornan, Jeff Settleman
Cell Cycle (Georgetown, Tex.)|August 20, 2009
Oncogenic K-ras "addiction" and synthetic lethalityAnurag Singh, Jeff Settleman
Cancer Letters|February 17, 2009
Targeting the RAF-MEK-ERK pathway in cancer therapyClara Montagut, Jeff Settleman
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2009
Personalized cancer therapy with selective kinase inhibitors: an emerging paradigm in medical oncologyUltan McDermott, Jeff Settleman
Pageof 7

Showing results (1-10 of 65) with videos related to

Sort By:
Pageof 7
Oncotarget|February 7, 2015
Predicting response to HER2 kinase inhibitionJeff Settleman
Seminars in Oncology|April 28, 2009
Cell culture modeling of genotype-directed sensitivity to selective kinase inhibitors: targeting the anaplastic lymphoma kinase (ALK)Jeff Settleman
Cancer Cell|October 6, 2009
A therapeutic opportunity in melanoma: ErbB4 makes a mark on skinJeff Settleman
Genome Medicine|July 18, 2014
Optimizing the treatment of BRAF mutant melanomaJeff Settleman
Nature|January 7, 2016
Cancer: Bet on drug resistanceJeff Settleman
BMC Medicine|December 17, 2009
Integrating complex genomic datasets and tumour cell sensitivity profiles to address a 'simple' question: which patients should get this drug?Cyril Benes, Jeff Settleman
Current Biology : CB|September 28, 2010
Cancer: miRNA addiction - depending on life's little thingsDavid Dornan, Jeff Settleman
Cell Cycle (Georgetown, Tex.)|August 20, 2009
Oncogenic K-ras "addiction" and synthetic lethalityAnurag Singh, Jeff Settleman
Cancer Letters|February 17, 2009
Targeting the RAF-MEK-ERK pathway in cancer therapyClara Montagut, Jeff Settleman
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2009
Personalized cancer therapy with selective kinase inhibitors: an emerging paradigm in medical oncologyUltan McDermott, Jeff Settleman
Pageof 7